• MT10 Is Ethnicity an Effect Modifier Between FLT3 Inhibitors and Salvage Therapy for Relapsed and Refractory Acute Myeloid Leukemia?

    Dec 1, 2022, 00:00

  • PCR257 Humanistic Burden Pre and Post COVID-19 on Caregivers of Cancer Patients in Japan and China: A NHWS Survey

    Dec 1, 2022, 00:00

  • CO61 Clinical Profile and Healthcare Resource Use of ANCA-Associated Vasculitis: A Real-World Analysis in Italy

    Dec 1, 2022, 00:00

  • SA47 Clinical Effectiveness of Osimertinib in Non-Small Cell Lung Cancer Patients With EGFR Mutation Between Plasma and Tissue Re-Biopsy: A Systematic Review and Meta-Analysis of Real-World Evidence

    Dec 1, 2022, 00:00

  • MSR41 Predicting Antimicrobial Resistance in Uncomplicated Urinary Tract Infections Using Machine Learning

    Dec 1, 2022, 00:00

  • MSR18 Modeling and Comparison of Non-Disease-Related Survival (NDRS) Using Local Lifetables and Reported Trial Data: A Case Study From Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma (MIUC)

    Dec 1, 2022, 00:00

  • CO23 Validating the Results of a Matching Adjusted Indirect Comparison (MAIC) in MET Exon 14 (METex14) Skipping Non-Small Cell Lung Cancer (NSCLC)

    Dec 1, 2022, 00:00

  • MT37 Comparative Analysis of Intra-Operative Transfusion Rates: Surgical Modality Comparison Using Japanese Real-World Database

    Dec 1, 2022, 00:00

  • EE20 Cost-Minimization Analysis for Treating T1DM and T2DM With Toujeo in Turkiye

    Dec 1, 2022, 00:00

  • HPR60 A Review on Policies Adopted and Existing Drug Regulation Amended for Speedy Development of Vaccines in India

    Dec 1, 2022, 00:00

  • HTA95 Analysis of Neurological Conditions Submissions to the National Institute for Health and Care Excellence (NICE) and the Scottish Medicines Consortium (SMC) From 2001 to 2021

    Dec 1, 2022, 00:00

  • HSD29 Factors Influencing Deprescribing Activities in the Management of Hospitalized Patients in Polytherapy

    Dec 1, 2022, 00:00

  • HPR195 Assessing the Adoption of Sustainability Criteria Within National Healthcare Procurement Policies in Europe

    Dec 1, 2022, 00:00

  • EE87 Are Landmark Survival Models Accepted in National Institute for Health and Care Excellence Health Technology Evaluations?

    Dec 1, 2022, 00:00

  • HPR4 ISPOR HEOR Trends Over Time: What Is the Influence of Macro HTA Changes?

    Dec 1, 2022, 00:00

  • EE276 The Budget Impact of Introducing a Rapid Polymerase Chain Reaction Test for the Detection of Influenza and Respiratory Syncytial Virus in China

    Dec 1, 2022, 00:00

  • MSR77 Bayesian Hierarchical Model-Based Network Meta-Analysis to Overcome Survival Extrapolation Challenges Caused by Immature Data: Application in Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) PD-L1>1%

    Dec 1, 2022, 00:00

  • HPR8 An Analysis of Risk Sharing Arrangements (RSAS) Between 2013 and 2021 in Australia

    Dec 1, 2022, 00:00

  • HTA56 Is Evidence on Environmental Impact Included in Health Technology Assessment and Does It Influence Decision-Making?

    Dec 1, 2022, 00:00

  • HTA196 Influence of REvalMED Pilot Program on Drug Evaluations in Spain: An Analysis of Therapeutic Positioning Reports

    Dec 1, 2022, 00:00

  • EE669 Use of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections in the Spanish Hospital Setting: A Comparative Cost Analysis

    Dec 1, 2022, 00:00

  • EPH134 Economic and Utility Evidence for Metastatic Synovial Sarcoma and Myxoid Round Cell Liposarcoma: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • EE24 Health Economic Evaluation of Replacing PCV13 With PCV15 in the Danish Childhood Vaccination Programme

    Dec 1, 2022, 00:00

  • EE672 Cost-Effectiveness Evaluation of Human Papilloma Virus Test in Comparison With Cytology From the Chilean Public System Perspective

    Dec 1, 2022, 00:00

  • CO142 Secondary Malignancies After Radiotherapy for Prostate Cancer: A Population-Based Study

    Dec 1, 2022, 00:00

  • RWD47 Use of Radiotherapy in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET) in Italy: A Real-World Data Analysis

    Dec 1, 2022, 00:00

  • SA42 The Proliferation of Living Systematic Reviews (LSRS) - Dead on Arrival? A Review of LSR Methodology

    Dec 1, 2022, 00:00

  • EE324 Cost-Effectiveness analysis of Atezolizumab as Adjuvant Treatment of Patients With Stage II-IIIA Non-Small Cell Lung Cancer, With Pd-L1≥50% of Tumor Cells, in France

    Dec 1, 2022, 00:00

  • EE32 Selection of Key Performance Indicators for an Economic Evaluation of Artificial Intelligence Technologies. The Case of Hosmartai (HORIZON 2020 Funded Program)

    Dec 1, 2022, 00:00

  • OP12 Findings From the 2022 International Society for Pharmacoeconomics and Outcomes Research Student Benefit Survey

    Dec 1, 2022, 00:00

  • CO83 Reduction of Transfusion Requirements and Length of Hospital Stay in Patients Undergoing Major Planned Surgery After the Implementation of Patient Blood Management (PBM) in Spain

    Dec 1, 2022, 00:00

  • HPR186 The Optimized Patient Treatment Initiative (OPT-IN): Choosing the Right Therapy, for the Right Patient, at the Right Time

    Dec 1, 2022, 00:00

  • EE481 Cost-Effectiveness of Empagliflozin for Patients With Heart Failure Irrespective of Ejection Fraction in England

    Dec 1, 2022, 00:00

  • EE604 Cost-Benefit Analysis of the New Jersey Prescription Drug Monitoring Program

    Dec 1, 2022, 00:00

  • MSR85 Performance Comparison of Unanchored Matching-Adjusted Indirect Comparison and Naïve Treatment Indirect Comparison on Survival Outcomes: A Simulation Study

    Dec 1, 2022, 00:00

  • HTA49 Implementation of Equity as an Element of Value in Health Care Technology Assessments in Europe

    Dec 1, 2022, 00:00

  • HTA241 Rare Diseases: The Role of Managed Access

    Dec 1, 2022, 00:00

  • EE153 Cost From Asparaginase Utilization in the Treatment of Acute Lymphoblastic Leukaemia in Hong Kong Paediatrics Population According to CCCG-2015 Protocol

    Dec 1, 2022, 00:00

  • MSR104 Assessing the Impact of Integrating Extrapolated Long-Term Outcomes Into Elicitation of Unreported Subgroup-Specific Survival in Randomized Controlled Trials (RCTS): Insights From Advanced Stage Gastrointestinal Cancers

    Dec 1, 2022, 00:00

  • EE149 Cost-Effectiveness of Cladribine Tablets and Dimethyl Fumarate in the Treatment of Relapsing Remitting Multiple Sclerosis in Spain

    Dec 1, 2022, 00:00

  • EE416 Cost-Effectiveness of Pembrolizumab Monotherapy for First-Line Treatment in Adult Patients with Microsatellite Instability High/Mismatch Repair-Deficient Metastatic Colorectal Cancer From a French Perspective

    Dec 1, 2022, 00:00

  • HSD104 Positions of SGLT2-Inhibitors in Treatment Algorithms for Heart Failure and Chronic Kidney Disease: Time to Recognise Their Value Beyond Type 2 Diabetes Management

    Dec 1, 2022, 00:00

  • PCR252 Patient and Caregiver Burden Associated With Caring for a Child With Alagille Syndrome: Mixed-Methods Development of Health State Vignettes

    Dec 1, 2022, 00:00

  • EPH20 Real-World Effectiveness of Palbociclib With Concomitant Proton Pump Inhibitor in Patients With Breast Cancer in South Korea: A Retrospective Cohort Study

    Dec 1, 2022, 00:00

  • SA8 Impact of the COVID-19 Pandemic on Health Care Resource Utilisation and Costs in COPD in England: A Population-Based Study

    Dec 1, 2022, 00:00

  • RWD95 Exploring the Burden of COVID-19 on Suicides and Suicidal Attempts (SSA) in Pre- and During-COVID-19 Pandemic Using Real-World Data

    Dec 1, 2022, 00:00

  • RWD27 Access to Social Security Among Multiple Sclerosis Patients in Italy

    Dec 1, 2022, 00:00

  • CO174 A Comparison of Stan Versus WinBUGS Software for Conducting Bayesian Network Meta-Analyses of Binary Outcomes

    Dec 1, 2022, 00:00

  • EE219 Cost-Effectiveness Analysis of the Use of Indoscyanine Green in Patients Undergoing Laparoscopic Cholecystectomy to Avoid Biliary Tract Injuries From the Perspective of the Colombian Health System

    Dec 1, 2022, 00:00

  • HPR178 Evaluation of Total Health Expenditures in OECD Countries for the Years 2000, 2010 and 2019

    Dec 1, 2022, 00:00

  • EPH11 Modeling the Public Health Impact of a Universal Rotavirus Program in the Netherlands

    Dec 1, 2022, 00:00

  • HTA77 The Use and Acceptability of External Comparator Studies to Support Hemato-Oncology Single-Arm Trial Submissions to Health Technology Assessment Bodies

    Dec 1, 2022, 00:00

  • EE326 Alleviating the Burden of Iron Deficiency in Heart Failure: A Multinational European Study

    Dec 1, 2022, 00:00

  • RWD14 Approaches to Selecting ‘Time Zero’ in External Control Arms with Multiple Potential Entry Points: A Simulation Study of Eight Approaches

    Dec 1, 2022, 00:00

  • EE2 Health Outcome in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma Treated With First-Line Sintilimab Plus Cisplatin and Paclitaxel Versus Cisplatin and Paclitaxel

    Dec 1, 2022, 00:00

  • PCR89 Qualitative Research to Understand the Lived Experience of Patients with Dry Eye Disease (DED), Meibomian Gland Dysfunction (MGD), and Sjogren's Syndrome Dry Eye Disease (SS-DED)

    Dec 1, 2022, 00:00

  • HTA171 Are Global Trials Good Enough to Support the Reimbursement of a New Technology in Asia? A Review of Asian HTA Submissions

    Dec 1, 2022, 00:00

  • HTA76 Clinical Expert Opinion in Health Technology Assessment Submissions to a National HTA Agency in Ireland

    Dec 1, 2022, 00:00

  • HTA206 Use of Real-World Data in Systematic Literature Reviews Conducted for Health Technology Assessment Submissions in Europe

    Dec 1, 2022, 00:00

  • EE329 Public Health and Economic Impact of a Gender-Neutral Quadrivalent Human Papillomavirus Vaccination Program in El Salvador

    Dec 1, 2022, 00:00

  • EE305 Burden of Disease and Cost of Illness of Atopic Dermatitis (AD)

    Dec 1, 2022, 00:00

  • HTA17 Cost-Effectiveness Analysis of Tocilizumab for The Treatment of COVID-19 in Hospitalised Patients on Corticosteroids, From the Italian NHS Perspective

    Dec 1, 2022, 00:00

  • PCR224 Acceptability and Usability of the Electronic Hidradenitis Suppurativa Quality of Life Questionnaire

    Dec 1, 2022, 00:00

  • HTA194 A Review of Oncology Submissions to NICE to See How Often Disease-Specific Quality of Life Data Have Been Accepted

    Dec 1, 2022, 00:00

  • HTA248 Could Early Scientific Advice Have Improved Outcomes in Cost-Effectiveness Markets?

    Dec 1, 2022, 00:00

  • PCR192 Treatment Burden and Its Relationship With Health-Related Quality of Life, Work Productivity and Activity Impairment in Adults With Severe Non-Inhibitor Hemophilia A in the United States: Data Analysis From the CHESS US+ Study

    Dec 1, 2022, 00:00

  • HTA92 10 Years of AMNOG: Importance of Real-World Evidence Studies in the German Benefit Assessment Process

    Dec 1, 2022, 00:00

  • RWD152 Hospital Outcomes and Costs for Prostate Cancer Patients With Comorbid Heart Failure by Age Group: An Analysis of the U.S. Nationwide Inpatient Sample

    Dec 1, 2022, 00:00

  • EE605 Feasibility Assessment of Using MiToS Staging System for Conducting Health Economic Analysis in Amyotrophic Lateral Sclerosis (ALS)

    Dec 1, 2022, 00:00

  • PCR144 International Adaptation and Linguistic Validation of the Hypoparathyroidism Daily Diary of Symptom Experience (HPT-DD-SE) and the Hypoparathyroidism Life Impact Questionnaire (HPT-LIQ)

    Dec 1, 2022, 00:00

  • EE583 Cost-Effectiveness of Dapagliflozin in the Treatment of Chronic Symptomatic Heart Failure With Reduced Ejection Fraction in the Netherlands

    Dec 1, 2022, 00:00

  • RWD67 Association of COVID-19 With Venous Thrombosis and Arterial Thrombosis

    Dec 1, 2022, 00:00

  • EE37 Cost-Utility Analysis of Elecsys Gaad Algorithm Versus Ultrasound Plus -Fetoprotein (AFP) for HCC Surveillance in Patients With Compensated Liver Cirrhosis in the United Kingdom (UK)

    Dec 1, 2022, 00:00

  • MSR24 Can Artificial Intelligence Separate the Wheat From the Chaff in Systematic Reviews of Health Economic Papers?

    Dec 1, 2022, 00:00

  • Development of the Bleeding and Pelvic Discomfort Scale for Use in Women With Heavy Menstrual Bleeding Associated With Uterine Fibroids

    Dec 1, 2022, 00:00

  • HTA103 Revalmed – What Is the Potential Impact of This New Process on the Spanish Market Access System?

    Dec 1, 2022, 00:00

  • EE202 Estimating the Public Health Benefits of Preventing Herpes Zoster and Postherpetic Neuralgia in Greece by Zoster Vaccines: A Modelling Study

    Dec 1, 2022, 00:00

  • RWD22 Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) Management in Belgium: A Longitudinal Pharmacy Database Study

    Dec 1, 2022, 00:00

  • MSR95 Use of Generalized F Parameterization in Long-Term Extrapolation for Adjuvant Cancer Therapies

    Dec 1, 2022, 00:00

  • MSR129 Limitations and Opportunities for Identifying Outcome Prognostic Factors in the Context of Small Samples

    Dec 1, 2022, 00:00

  • P42 Using Bayesian Evidence Synthesis Methods to Incorporate Real-World Evidence in Surrogate Endpoint Evaluation

    Dec 1, 2022, 00:00

  • EE632 Winning the COVID-19 Vaccine Ra How to Launch a Premium Priced COVID-19 Vaccine in a Competitive and Saturated Cost-Effectiveness Market

    Dec 1, 2022, 00:00

  • EPH33 Assessing the Validity of English Linked Routine Healthcare Resource Utilisation Data in the Investigation of Triple Therapy Effectiveness (INTREPID Trial)

    Dec 1, 2022, 00:00

  • EPH65 Assessment of Enzyme Preparations Consumption in Ukraine in Comparison With Other Countries of the World

    Dec 1, 2022, 00:00

  • HSD92 Operational Savings Generated in an Integrated Care Clinic for Immune-Mediated Skin Disorders

    Dec 1, 2022, 00:00

  • HSD37 Information Seeking Behaviour of the Hungarian Population Regarding Antibiotics and Common Infectious Ailments: An Infodemiological and Thematic Analysis Using Google TRENDSTM

    Dec 1, 2022, 00:00

  • EE9 Cost-Effectiveness Analysis of Dupilumab, Mepolizumab and Benralizumab for Severe Eosinophilic Asthma With Blood Eosinophil Count ≥300 Cells/Mcl in the Brazilian Private Healthcare Perspective

    Dec 1, 2022, 00:00

  • MSR44 An Extended Simulated Treatment Comparison Approach Accounting for Unobserved Confounding in Indirect Comparisons for Single-Arm Trials

    Dec 1, 2022, 00:00

  • CO178 Cardiovascular, Neurological, and Ocular Complications of COVID-19 Among Indian Patients – A Targeted Literature Review

    Dec 1, 2022, 00:00

  • EE15 Cost-Consequence Analysis of Ofatumumab in Comparison With Other Disease-Modifying Therapies and Best Supportive Care for the Treatment of Relapsing-Remitting Multiple Sclerosis in Canada

    Dec 1, 2022, 00:00

  • MT11 A Cost-Effectiveness Analysis of Acrysof IQ Vivity Intraocular Lens (IOL) From Private Health Fund Perspective in Australia

    Dec 1, 2022, 00:00

  • CO113 Systematic Review and Network Meta-Analysis of Durability of Faricimab in Neovascular Age-Related Macular Degeneration

    Dec 1, 2022, 00:00

  • EE681 Costs of Treating Acute Hereditary Angioedema (HAE) Attacks With C1 Inhibitors in Five Central and Eastern European Countries

    Dec 1, 2022, 00:00

  • HPR118 An Updated Estimate of the Direct Cost of the COVID-19 Pandemic for the Greek Healthcare System

    Dec 1, 2022, 00:00

  • HTA146 From Vague to Valid – Chances and Risks of Benefit Re-Assessments Due to New Scientific Evidence in Germany

    Dec 1, 2022, 00:00

  • MSR82 Dealing With Non-Comparative Data: Proposed Alternatives and Considerations to Conduct Indirect Treatment Comparisons (ITCs)

    Dec 1, 2022, 00:00

  • HTA94 Two South African Health Technology Assessment Methods Guides: Which One Is More Suitable for the Assessment and Appraisal of Medicines?

    Dec 1, 2022, 00:00

  • EE61 Economic Evaluation of Therapies Submitted With Non-Comparative Single Arm Phase II Data: A Comparison of NICE and Has Efficiency Opinions

    Dec 1, 2022, 00:00

  • EE663 Estimating the Cost of an Outpatient Department Visit in the Irish Public Health Care System

    Dec 1, 2022, 00:00

  • PCR169 Patient Involvement in Regulatory and HTA Processess: A Call for Enhanced Alignment

    Dec 1, 2022, 00:00

  • HSD49 Improving Influenza Vaccination Rates: Evaluation of Pharmacy Vaccination Model Project During COVID-19 Pandemic in Germany

    Dec 1, 2022, 00:00

  • EE260 An Early Cost-Effectiveness Analysis of a New Continuous Compartment Pressure Monitoring Device in Tibial Fracture Patients Who Are at Risk of Developing Acute Compartment Syndrome (ACS)

    Dec 1, 2022, 00:00

  • EPH171 Delivery Outcomes in the United States Among Women With Commercial or Medicaid Insurance During the COVID-19 Pandemic

    Dec 1, 2022, 00:00

  • EE380 The Health and Economic Impact of Sodium-Glucose Co-Transporter-2 Inhibitors (SGLT2IS) in the Netherlands

    Dec 1, 2022, 00:00

  • HPR51 Identification and Quantification of Implementation Challenges and Costs Associated With Short-Term National-Level Vaccine Switches

    Dec 1, 2022, 00:00

  • MSR64 Utility Analysis Methods: Can One Method Fit It All or Is a Case-By-Case Approach Required?

    Dec 1, 2022, 00:00

  • HSD30 Analysis of the Balanced Scorecard's Financial Subdimensions in Health Care Organizations During the COVID-19 Pandemic

    Dec 1, 2022, 00:00

  • EPH80 Influence of Socio-Demographic Factors on Internet Addiction in Students of Professional Courses in Dakshina Kannada District, Karnataka: A Cross-Sectional Study

    Dec 1, 2022, 00:00

  • RWD4 Health Care Resource Utilization and Cost (HCRU) Among Treatment-Experienced People Living With HIV (PLWH) Switching to Single Tablet Regimen (STR) or Multi-Tablet Regiment (MTR) Triple Therapy Since 2018

    Dec 1, 2022, 00:00

  • HPR100 Analysis of the Drug Price Level of Anticancer and Rare Disease Drugs After the Implementation of Economic Evaluation Exemption in South Korea

    Dec 1, 2022, 00:00

  • CO122 Mapping the Characteristics of Network Meta-Analyses on Antithrombotic Therapies: An Overview and Critical Appraisal

    Dec 1, 2022, 00:00

  • EE462 Cost-Effectiveness of Nivolumab for the Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma Patients With High Risk of Recurrence and Tumor Cell Pd-L1 Expression ≥ 1% in Sweden

    Dec 1, 2022, 00:00

  • EE27 Cost-Effectiveness and Cost-Utility Analysis of Somatrogon Once-Weekly Injectable vs Daily Growth Hormones for Treating Pediatric Growth Hormone Deficiency

    Dec 1, 2022, 00:00

  • HTA215 Comparison of French HTA Parallel Appraisal Performed by the Economic and Public Health Committee (CEESP) and the Transparency Committee (TC) for a Same Product: Are the Conclusions of the Two Committees Consistent?

    Dec 1, 2022, 00:00

  • SA68 Protocol for the First Global Study Capturing the Patient-Reported Impact of Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia (ALSP) in the Real-World Setting Using a Smartphone Application

    Dec 1, 2022, 00:00

  • EE565 Cost-Utility Analysis of Dupilumab in Adults and Adolescents With Uncontrolled Persistent Severe Asthma in Portugal

    Dec 1, 2022, 00:00

  • HPR180 Eligibility of Orphan Drugs for Preferential Reimbursement in Egypt

    Dec 1, 2022, 00:00

  • HTA182 Time to Access Pediatric/Adolescent vs Adult Medicinal Products in Greece

    Dec 1, 2022, 00:00

  • MSR108 Identifying Diabetes Types by Modelling Drug Consumption and Patient Profile Data From Pharmacies

    Dec 1, 2022, 00:00

  • RWD82 Influence of the COVID-19 Pandemic on Patients Receiving Oral Anticoagulants for the Treatment of Non-Valvular Atrial Fibrillation

    Dec 1, 2022, 00:00

  • RWD16 Role of Real-World Evidence for Treatments Granted Access Under Cancer Drugs Fund: Lessons and Insights From Review of NICE Technology Assessment Reports (2019-2022)

    Dec 1, 2022, 00:00

  • PCR36 Content Validity, Acceptability, and Usability of the Electronic Hidradenitis Suppurativa Symptom Daily Diary and the Electronic Hidradenitis Suppurativa Symptom Questionnaire

    Dec 1, 2022, 00:00

  • HTA21 Evolving Landscapes for Advanced Therapy Medicinal Products (ATMPS): Access in the US, UK, EU

    Dec 1, 2022, 00:00

  • HTA129 The Evolution of Cost Comparison at NICE: What Can We Learn From Fast-Track Appraisals?

    Dec 1, 2022, 00:00

  • HSD38 Assessing the Changes of Health Spa Demand in Hungary Between 2012 and 2019

    Dec 1, 2022, 00:00

  • EE370 Cost Effectiveness Evaluation of Dapagliflozin in the Treatment of Chronic Kidney Disease in Mexico

    Dec 1, 2022, 00:00

  • MSR107 Can Artificial Intelligence (AI) Be Used to Improve the Efficiency of Title and Abstract Citation Screening?

    Dec 1, 2022, 00:00

  • RWD148 Patient Reported Outcomes With Chemotherapy of Breast Cancer: An Analysis of Breast Cancer Registry Publications Between 2012-2022

    Dec 1, 2022, 00:00

  • RWD38 Genetic Mutational Testing in CLL Patients in the Routine Care of Eight EU Member States

    Dec 1, 2022, 00:00

  • HTA211 Are Surrogate Endpoints a Way Forward in Non-Small Cell Lung Cancer (NSCLC)? A Comparison of HTA Outcomes Across Germany, France, and the UK

    Dec 1, 2022, 00:00

  • PCR11 Quality of Life Analysis of Hypoglossal Nerve Stimulation with INSPIRE® Device in the Treatment of Patients With Obstructive Sleep Apnea Intolerant to Continuous Positive Airway Pressure Therapy

    Dec 1, 2022, 00:00

  • RWD146 Economic Burden Associated With Streptococcus Suis Infection Treatment in Northern Thailand: A Hospital-Based Observational Study

    Dec 1, 2022, 00:00

  • EPH91 Association Between Mental Disorders and COVID-19 Outcomes in Hospitalized Patients in Fran A Retrospective Nationwide Population-Based Study

    Dec 1, 2022, 00:00

  • EE53 The Net Monetary Benefit of Introducing Sodium-Glucose Cotransporter-2 Inhibitors in Middle-Income Countries

    Dec 1, 2022, 00:00

  • HPR201 Combination Policy – Value of Combination Treatments and the Future in Cancer Management

    Dec 1, 2022, 00:00

  • EE82 Early Economic Modelling of Cancer Therapy

    Dec 1, 2022, 00:00

  • Disclosure Information

    Dec 1, 2022, 00:00

  • RWD166 Prevalence of PD-L1 and Other Selected Biomarkers in Advanced Urothelial and Esophageal Carcinoma and Advanced Head and Neck Squamous Cell Carcinoma in Two Reference Institutions of Colombia

    Dec 1, 2022, 00:00

  • EE628 Economic Benefits of Cangrelor in Patients With Coronary Artery Disease Undergoing Percutaneous Coronary Intervention: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • HSD56 Assessing Effects of the IEHTC Program on Clinical Outcomes and Cost of Care in a Healthcare Provider Shortage Area in USA

    Dec 1, 2022, 00:00

  • MSR96 A Methodological Study to Compare Alternative Modes of Administration for Undertaking Preference-Elicitation Studies

    Dec 1, 2022, 00:00

  • HTA59 Association Between Information Sources of Manufacturer-Proposed Utility Values and the NICE Technology Appraisal Committee's Acceptance

    Dec 1, 2022, 00:00

  • HTA264 Why Doesn't Environmental Impact Play a Bigger Role in Health Economic Evaluation and Health Technology Assessment – A Systematic Literature Review

    Dec 1, 2022, 00:00

  • PCR69 Rheumatologists´ Perspective on Patient Reported Outcomes to Promote Shared Decision-Making in Patients With Rheumatoid Arthritis

    Dec 1, 2022, 00:00

  • HSD28 Most Common Treatments in Patients With Treatment Resistant Depression Based on European Cohort Study Real-World Evidence

    Dec 1, 2022, 00:00

  • EE525 The Economic Value of Insulin Glargine 300 U/Ml (Gla-300) in People ≥18 Years of Age With Type 2 Diabetes Mellitus: A Value-Based Economic Model From a U.S. Payer Perspective

    Dec 1, 2022, 00:00

  • EPH23 An Epidemiological Estimate of the Prevalence of the Coded Nonalcoholic Steatohepatitis (NASH) Population in the US Using an Administrative Claims Dataset

    Dec 1, 2022, 00:00

  • EE524 The Incremental Cost-Effectiveness Ratio (ICER) Thresholds in Central and Eastern European Countries

    Dec 1, 2022, 00:00

  • MSR109 Can Jointly Modelling PFS and OS With Mixture Cure Models Overcome Data Immaturity Problems?

    Dec 1, 2022, 00:00

  • EE353 Resource Utilisation and Healthcare Costs Among Patients With Major Depression and Active Suicidal Ideation With Intent in Italy: Initial Findings From the Arianna Observational Substudy

    Dec 1, 2022, 00:00

  • EE426 Budget Impact Analysis of Atezolizumab in 1ST Line Treatment for Patients With PD-L1 High Metastatic NSCLC From a French Payor Perspective

    Dec 1, 2022, 00:00

  • EE591 Economic Modeling Considerations for Rare Neurodegenerative Diseases of Infancy and Early Childhood

    Dec 1, 2022, 00:00

  • EE69 Cost Utility and Budget Impact Analyses of Closed Loop Upper Airway Stimulation (UAS) for the Treatment of Moderate to Severe Obstructive Sleep Apnea From an Australian Health Care System Perspective

    Dec 1, 2022, 00:00

  • HTA152 Practical Challenges of Implementing a New Patient-Reported Outcome (PRO) in Oncology Under the German Pharmaceutical Market Restructuring Act (AMNOG) - Results From a Qualitative Focus Group Study

    Dec 1, 2022, 00:00

  • EE242 Cost-Effectiveness Analysis of Entrectinib for Treatment NTRK Fusion-Positive Tumors in Czech Republic

    Dec 1, 2022, 00:00

  • SA48 Identifying Flares in Lupus Nephritis Patients by Combining Structured and Unstructured Medical Records With Lab Data

    Dec 1, 2022, 00:00

  • CO121 Treat-and-Extend Versus As-Needed Regimen in Neovascular Age-Related Macular Degeneration: 1-Year Findings From a Network Meta-Analysis

    Dec 1, 2022, 00:00

  • EE490 Attributable Cost of Adult Respiratory Syncytial Virus Illness Beyond the Acute Phase

    Dec 1, 2022, 00:00

  • EE290 Cost-Effectiveness of Intravenous Iron Formulations in Patients With Iron Deficiency Anaemia and IBD in Sweden

    Dec 1, 2022, 00:00

  • CO160 Dependence Levels Derived From the Alzheimer's Disease Cooperative Study – Activities of Daily Living in People With Early (Prodromal-to-Mild) Alzheimer's Disease

    Dec 1, 2022, 00:00

  • HTA58 Does NICE’s STA Process Effectively Reward the Value of Double-Branded Oncology Combinations, When Compared to Oncology Monotherapies?

    Dec 1, 2022, 00:00

  • CO51 Efficacy and Safety of Vonoprazan Triple Therapy (Vonoprazan, Amoxicillin, Clarithromycin) in Patients With Helicobacter Pylori Infection: Systematic Review Meta-Analysis of Randomized Controlled Trials

    Dec 1, 2022, 00:00

  • EE646 Systematic Review on Cost and Healthcare Resource Utilization in Immunoglobulin A Nephropathy (IgAN)

    Dec 1, 2022, 00:00

  • EPH125 Potential Health Effects of a Blood-Based Genomic Test Used to Prescreen Individuals Eligible for Lung Cancer Screening in the U.S.

    Dec 1, 2022, 00:00

  • EE451 A Narrative Review of The Economic Burden Attributable to Obesity and Overweight in China

    Dec 1, 2022, 00:00

  • EE476 Budget Impact Analysis of iGlarLixi for Treatment of T2DM in Algerian Setting

    Dec 1, 2022, 00:00

  • PCR220 Attitude Toward HPV Vaccination Among Mothers of Boys and Girls

    Dec 1, 2022, 00:00

  • P63 Patient-Reported Outcomes Following Treatment with Vimseltinib for Tenosynovial Giant Cell Tumour in a Phase 2 Expansion Study

    Dec 1, 2022, 00:00

  • SA37 Cultural Adaptation and Sociometric Analysis of Aberdeen Varicose Vein Questionnaire

    Dec 1, 2022, 00:00

  • EE634 Disease Burden Analysis of Prophylactic Treatment Versus On-Demand Treatment for Adult Patients With Moderate-to-Severe Haemophilia A in China

    Dec 1, 2022, 00:00

  • EPH31 Risk of Hospital Admission or Emergency Department Presentation Due to Diabetes Complications: A Retrospective Cohort Study in Tasmania, Australia

    Dec 1, 2022, 00:00

  • HPR56 The Rise of Real-World Evidence (RWE) in EU Marketing Authorization Decisions – Past, Present, and Future

    Dec 1, 2022, 00:00

  • EE256 Budget Impact Analysis of the Introduction of a Novel Gene Expression Biomarker Test for Early-Stage Breast Cancer Patients in Cyprus

    Dec 1, 2022, 00:00

  • MSR16 Mixture-Cure Modelling of Overall Survival of Patients With Metastatic Non-Small Cell Lung Cancer Receiving Nivolumab + Ipilimumab in CheckMate 277 – Updated With 5 Years of Follow-up

    Dec 1, 2022, 00:00

  • EPH128 Hospitalizations for Post-Chemotherapy Red Blood Cell Transfusions in France, 2017–2020

    Dec 1, 2022, 00:00

  • MSR134 Optimizing Fractional Polynomials by Using Variable Powers

    Dec 1, 2022, 00:00

  • CO13 Evidence Gap Analysis of the Burden of Illness and Treatment of Primary Immune Thrombocytopenia

    Dec 1, 2022, 00:00

  • RWD23 Healthcare Disparity in Change in Clinical Outcomes in Multiple Myeloma Patients

    Dec 1, 2022, 00:00

  • CO77 Use of Interrupted Time-Series Analyses in Evaluating Health Economic Outcomes Following Implementation of Multilayer Water-Tight Wound Closure in a Primary Total Joint Arthroplasty Population

    Dec 1, 2022, 00:00

  • HSD8 Cancer Survivorship Surveillance Patterns Among Earlier-Staged Lung Cancer (LC) Patients

    Dec 1, 2022, 00:00

  • EE150 Resource Utilisation in Non-Small Cell Lung Cancer With Brain/CNS Metastases in Europe, Asia, US and Brazil

    Dec 1, 2022, 00:00

  • MSR131 Characterizing the Impact of the Shared-Effect Modification Assumption on Population-Adjusted Indirect Comparisons

    Dec 1, 2022, 00:00

  • RWD129 A Comparison of ICU Admission Rate and Related Cost Among Patients Taking Nirmatrelvir and Ritonavir Combination Versus Molnupiravir for Treatment of Mild to Moderate COVID-19 in the US

    Dec 1, 2022, 00:00

  • EE188 Health and Economic Impact of 23-Valent Pneumococcal Polysaccharide Vaccine in the Older Adult Immunization Program in Mexico

    Dec 1, 2022, 00:00

  • CO125 Characteristics of Asthma Patients at GINA's Higher Steps on OCS Treatment: A Cross-Sectional Study in Portuguese Community Pharmacies (EmOCS Study)

    Dec 1, 2022, 00:00

  • HSD5 Patients Satisfaction for Transanal Irrigation and Intermittent Catheterization Service of Delivery

    Dec 1, 2022, 00:00

  • EE678 Cost Effectiveness of Cognitive Behavioural Therapy for Psychosis Through Reduced Hospitalisation

    Dec 1, 2022, 00:00

  • EE528 Resource Use and Costs Associated With Computerized Decision Support System for Managing Patients With Atrial Fibrillation

    Dec 1, 2022, 00:00

  • EE345 Cabotegravir and Rilpivirine Long-Acting Antiretroviral Therapy Administered Every 2-Months Is Cost Effective for the Treatment of HIV-1 in Spain

    Dec 1, 2022, 00:00

  • EE548 Value Based Reimbursement Decision Making Parameters for Acute on Chronic Liver Failure – Potential Evaluation Framework on Acute Rare Diseases

    Dec 1, 2022, 00:00

  • EE252 Budget Impact of a Minimally Invasive Surgical Treatment for Benign Prostatic Hyperplasia in Spain

    Dec 1, 2022, 00:00

  • HPR203 Terminated NICE Appraisals – A Hidden Driver Behind the UK's Access Challenges?

    Dec 1, 2022, 00:00

  • HTA214 Distributional Cost-Effectiveness Analysis of Lung Cancer Treatments From an NHS England Perspective

    Dec 1, 2022, 00:00

  • EE239 Real-World Analysis and Economic Evaluation of the Freestyle Libre System in Selected Districts in Italy: The Reconnect Study

    Dec 1, 2022, 00:00

  • CO79 Post-Acute Myocardial Infarction: 90-Day Outcomes Assessment Becoming More Relevant and Critical Due to Patient Burden and Poor Outcomes

    Dec 1, 2022, 00:00

  • PCR281 Utility Studies in Rare Diseases: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • EE84 Cost of Follow-Up After an Ischemic Heart Disease Event in Patients With Atherosclerotic Cardiovascular Disease in Spain: Results From the Reality Study

    Dec 1, 2022, 00:00

  • HPR73 A Comparison of the Evolution of Payer Management Practices in Oncology in the United States, Germany, France, and the United Kingdom, Over the Past Five Years

    Dec 1, 2022, 00:00

  • EE272 A Pragmatic Literature Review on the Economic Cost Burden of Four Key Preventable Diseases in the UK

    Dec 1, 2022, 00:00

  • PCR271 Health-Related Quality of Life (HRQOL) by Line of Treatment, Treatment History, and Disease Status in Patients With Metastatic Urothelial Carcinoma (MUC) in EU-4 and the United Kingdom: Results From a Disease Specific Programme

    Dec 1, 2022, 00:00

  • PCR66 How Would the Choice of the Multi-Attribute Utility Instrument Affect the Cost-Effectiveness of Cancer Interventions? A Comparison of the FACT-8D and the AQoL

    Dec 1, 2022, 00:00

  • PCR40 Impact of Non-Pharmacological Interventions on Medication Adherence in Hypertension or Dyslipidemia: A Systematic Literature Review

    Dec 1, 2022, 00:00

  • EE485 Budget Impact Model (BIM) of the Newly Proposed Value-Based Positive Airway Pressure (PAP) Therapy Based on Telemonitoring in Patients With Obstructive Sleep Apnea (OSA) in Spain.

    Dec 1, 2022, 00:00

  • EE297 A Cost-of-Illness Study of the Economic Burden of Obsessive-Compulsive Disorder in the United Kingdom

    Dec 1, 2022, 00:00

  • MSR57 Study of Time-Course Relationship Using Model-Based Network Meta-Analysis: A Linear Time-Course Model

    Dec 1, 2022, 00:00

  • HPR101 Analyzing Substitution Effects in Financing of the Pharmaceutical Sector in Greece

    Dec 1, 2022, 00:00

  • SA81 Feasibility and Challenges of Virtual Time Trade-Off Interviews: The Case of the EQ-5D-3L Valuation Study in Jordan

    Dec 1, 2022, 00:00

  • EE375 Cost-Effectiveness Analysis of the Oncotype DX® Test to Reduce Under-Treatment in Patients With HR+/HER2- Node Negative Early-Stage Breast Cancer and Grade 2 T1C Tumours

    Dec 1, 2022, 00:00

  • HPR185 The International Impact of National Institute for Health and Care Excellence (NICE) Decisions

    Dec 1, 2022, 00:00

  • EE404 Forecast of Social and Economic Burden of HIV-Infection in Russia in Different Scenarios of Anti-HIV Policy up to 2035

    Dec 1, 2022, 00:00

  • EE616 Management of Chronic Lymphocytic Leukemia: What Impact on Consumption and Expenditure?

    Dec 1, 2022, 00:00

  • EE336 Budget Impact Analysis of Zanubrutinib for Patients With Treatment-Naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the United States

    Dec 1, 2022, 00:00

  • EPH195 Psychometric Evaluation of the Hungarian Version of Oxford Capabilities - Mental Health Questionnaire

    Dec 1, 2022, 00:00

  • PCR44 A Qualitative Study of Measuring Health Related Quality of Life in Migraine Patients: Comparing EQ-5D and MSQ V2.1 Questionnaires

    Dec 1, 2022, 00:00

  • P55 Creating a Web-Based Interactive Map Visualising the Geographic Variations of the Burden of Diabetes to Inform Policymaking: An Example From Tasmania, Australia

    Dec 1, 2022, 00:00

  • RWD142 General Vaccine Dispensing Patterns During the First Year of the COVID-19 Pandemic in South Africa

    Dec 1, 2022, 00:00

  • RWD115 Modelling the Effect of Multi-Indication Treatment in Patients With Multimorbidity Using Population-Scale Linked Electronic Health Records for Healthcare Policy and Decision-Making

    Dec 1, 2022, 00:00

  • CO109 What Does Real World Evidence Tells? A Case Analysis in Breast Cancer Using Pharmaceutical Consultation Data

    Dec 1, 2022, 00:00

  • EPH207 Epidemiology of Hospital Malnutrition With a Focus on Hospital Wards Where Malnutrition Is a Serious Problem

    Dec 1, 2022, 00:00

  • CO139 Augmenting Atrial Fibrillation Risk Prediction Tools – How Does Risk Differ by Prior Stroke Type?

    Dec 1, 2022, 00:00

  • MSR123 Use of Real-World Data in Cost-Effectiveness Analysis of Sequential Biologic Treatment for Rheumatoid Arthritis

    Dec 1, 2022, 00:00

  • EE40 Cost-Effectiveness of GLP-1 Receptor Agonists Versus Long-Acting Insulins in Type 2 Diabetes From the Healthcare Sector Perspective: A Model-Based Analysis Using Real-World Data

    Dec 1, 2022, 00:00

  • EE387 Major Ischemic or Hemorrhagic Events and Associated Costs Among Anticoagulated Patients With Non-Valvular Atrial Fibrillation in Switzerland

    Dec 1, 2022, 00:00

  • EE295 Indirect Treatment Comparison and Cost-Minimization Analysis of Riociguat Versus Selexipag in Patients With Pulmonary Arterial Hypertension

    Dec 1, 2022, 00:00

  • EPH178 Impact Assessment of the COVID-19 Pandemic on Varicella Incidence Across Europe Using Digital Epidemiology Methods

    Dec 1, 2022, 00:00

  • PCR146 Preferences for Toenail Onychomycosis Treatments Among Canadians With and Without Diabetes Mellitus: A Discrete Choice Experiment

    Dec 1, 2022, 00:00

  • PCR200 Measuring the Burden of Alopecia Areata With the European Quality of Life-5 Dimensions (EQ-5D): Results From a Real-World Survey in 5 European Countries

    Dec 1, 2022, 00:00

  • EE247 Public Health Impact of Switching From a Trivalent to a Quadrivalent Inactivated Influenza Vaccine in the Dominican Republic

    Dec 1, 2022, 00:00

  • P14 The Impact of Long-Term Follow-Up on Mean Survival Estimates From Immuno-Oncology Clinical Trials

    Dec 1, 2022, 00:00

  • MSR69 Challenges in Presenting Engagement Statistics in Real-World Digital Studies

    Dec 1, 2022, 00:00

  • HTA174 Analysis of NICE Fast Track Appraisals: What Are the Key Characteristics for Success?

    Dec 1, 2022, 00:00

  • HTA257 MOVe-OUT: A Trial of Two Halves – The Impact of Heterogeneity on Cost-Effectiveness Outcomes for COVID-19

    Dec 1, 2022, 00:00

  • EE396 Public Health Impact and Cost-Effectiveness of Herpes Zoster Vaccination for Older Adults in the Netherlands

    Dec 1, 2022, 00:00

  • HTA160 A Systematic Review and Meta-Analysis of the Janus Kinase Inhibitors Safety Profile in Relation to the Risks of Secondary Bacterial Infections

    Dec 1, 2022, 00:00

  • EPH168 Assessment of the Prevalence of Emotional Burnout Among Medical Workers in the Republic of Kazakhstan

    Dec 1, 2022, 00:00

  • HTA118 Cost-Effectiveness of Pressured-Controlled Intermittent Coronary Sinus Occlusion in ST-Elevated Myocardial Infarction: A Threshold Analysis for Italy on the Cost of the Device

    Dec 1, 2022, 00:00

  • EE642 Economic Impact Before and After Expensive Drug Reimbursement With Diabetic Macular Edema in South Korea

    Dec 1, 2022, 00:00

  • HSD42 Modelling Time and Costs Associated With Daratumumab Treatment Delivery in the Home Care Setting Versus the Hospital in Spain to Understand Potential Benefits to Patients and Hospitals

    Dec 1, 2022, 00:00

  • P44 Review of Methods Used to Estimate Treatment Effects Against Relevant Comparators Using Evidence From Single-Arm Studies in NICE Single Technology Appraisals

    Dec 1, 2022, 00:00

  • MSR139 Safe to Assume? Unpacking Regression Assumptions for Utility Data

    Dec 1, 2022, 00:00

  • EE456 Cost-Effectiveness of Tenofovir Alafenamide (TAF) for Treatment of Chronic Hepatitis B in Taiwan

    Dec 1, 2022, 00:00

  • EPH113 Influence of an Intervention to Inform Mothers About Breastfeeding Using a Logistic Regression Model: Should We Invest Into Breastfeeding Education in France?

    Dec 1, 2022, 00:00

  • HSD36 Generic Penetration in the Market for Antidiabetics, Lipid Modifying Agents and Psychoeleptics/Psychoanaleptics: A Comparative Analysis of Data From 18 European Markets

    Dec 1, 2022, 00:00

  • EE348 The Cost-Effectiveness of Belimumab for the Treatment of Patients With Systemic Lupus Erythematosus (SLE) in China

    Dec 1, 2022, 00:00

  • PCR149 Quality of Life of Patients With Chronic Wounds

    Dec 1, 2022, 00:00

  • RWD56 Machine Learning for Clustering Dyslipidemia Patients With Statin Intolerance in Germany

    Dec 1, 2022, 00:00

  • SA9 RWE Pathway: The State-of-the-Art of Patient Registries in Portugal

    Dec 1, 2022, 00:00

  • EE464 Is the Willingness to Pay for Years of Life in an Extreme Situation of the COVID Pandemic Closures Similar to the Willingness to Pay in Situations of Ordinary Basis? Comparison by Population Groups

    Dec 1, 2022, 00:00

  • EE660 Cost-Effectiveness of Personalized Nutrition Based on Omic Sciences in Adults With Abdominal Overweight or Obesity: A Within-Trial Analysis and Beyond-Trial Modelling in the United Kingdom and Poland

    Dec 1, 2022, 00:00

  • PCR39 Family Crises and Coping Mechanisms

    Dec 1, 2022, 00:00

  • PCR205 Use of the Patient-Reported Outcomes Measurement Information System (PROMIS) in Rare Disease Clinical Trials

    Dec 1, 2022, 00:00

  • CO96 Real-World (RW) Use of Cladribine Tablets in Portugal: A Two-Year Update of a Cohort Database

    Dec 1, 2022, 00:00

  • PCR218 Patient Characteristics and Persistence Among Commercially Insured Patients With Multiple Sclerosis Initiating Cladribine Tablets

    Dec 1, 2022, 00:00

  • EE195 Economic Burden of Cardiovascular Disease Among Commercially Insured Adults Diagnosed With Colorectal Cancer in the United States

    Dec 1, 2022, 00:00

  • EE543 Budget Impact Analysis of Gaucher Disease Pharmacologic Treatment in Colombia

    Dec 1, 2022, 00:00

  • SA10 Systematic Literature Review of Randomized Clinical Trials (RCTS) on Ivabradine (IVA) in Heart Failure (HF)

    Dec 1, 2022, 00:00

  • HSD62 An Analysis of the Status of Newborn Screening Programmes in the European Union and Its Upcoming Developments: What Does This Mean for New Drugs?

    Dec 1, 2022, 00:00

  • RWD110 Real World Outcomes in Patients with Advanced/Metastatic Solid Tumors Who Are Immuno-Oncology (IO) Naive and Received Second-Line Therapy: Analysis by Tumor Mutational Burden (TMB) Status

    Dec 1, 2022, 00:00

  • EE367 Budget Impact Analysis of Transcatheter Aortic Valve Replacement in Low, Intermediate, and High-Risk Patients With Severe Aortic Stenosis in Saudi Arabia

    Dec 1, 2022, 00:00

  • P4 Cost Analysis of Post-COVID-19 Healthcare Consumption in the Netherlands

    Dec 1, 2022, 00:00

  • EE417 Development and Application of a New Cost-Utility Model to Assess the Cost-Effectiveness of Palivizumab for the Prevention of Severe Respiratory Syncytial Virus (RSV) Infection in Moderate-to-Late Preterm Infants

    Dec 1, 2022, 00:00

  • CO135 Matching-Adjusted Indirect Comparison of Risdiplam Versus Nusinersen in Type 1 Spinal Muscular Atrophy: 2-Year Update

    Dec 1, 2022, 00:00

  • MSR98 Incorporating Covariates in Healthcare Decision-Making: Empirical Application of Methods in a Cost-Effectiveness Model for IVIG in Severe Sepsis

    Dec 1, 2022, 00:00

  • HTA144 Evolution and Implications of the Portuguese HTA Framework on Added Therapeutic Value in Patients’ Access to Innovation

    Dec 1, 2022, 00:00

  • EE168 Cost-Effectiveness Analysis of Darolutamide Plus Androgen Deprivation Therapy for Patients With High-Risk Non-Metastatic Castration-Resistant Prostate Cancer in China

    Dec 1, 2022, 00:00

  • HTA148 PRIME: Does Accelerated Marketing Authorization Translate Into Expedited Reimbursement and Patient Access?

    Dec 1, 2022, 00:00

  • EE309 Impact of Differential Baseline Utility Values: Atopic Dermatitis

    Dec 1, 2022, 00:00

  • EPH133 Cross-Sectional Research on the Development of Case Management Approach for Disability Patient Based on the Workability Index and Quality of Life Measures

    Dec 1, 2022, 00:00

  • CO75 Advanced Multi-Layer, Watertight Closure in Total Joint Replacement: A Retrospective Study

    Dec 1, 2022, 00:00

  • OP13 Drug Shortage Concepts Among Stakeholders in Saudi Arabia

    Dec 1, 2022, 00:00

  • EE332 Cost-Effectiveness Analysis of Using a Smartphone Application to Improve Timely Vaccination Among Children in the Zaatari Refugees Camp, Jordan

    Dec 1, 2022, 00:00

  • EE664 The Basis for a New Framework to Determine the Cost-Effectiveness Threshold

    Dec 1, 2022, 00:00

  • EE1 Healthcare Resource Utilization and Cost of Treatment-Resistant Depression: A Six-Year Trend and Comparative Analysis in Hong Kong

    Dec 1, 2022, 00:00

  • EE568 Tenecteplase or Alteplase for Acute Ischemic Stroke? A Cost-Effectiveness Analysis

    Dec 1, 2022, 00:00

  • HTA166 How Successful Has the Technical Engagement Phase of NICE Appraisals Been in Resolving Issues?

    Dec 1, 2022, 00:00

  • SA30 Evaluation of National Approvals and Data Collection Durations in Retrospective Noninterventional Medical Record Review Studies Conducted in the United States (US), Canada, Europe (EU), and Asia

    Dec 1, 2022, 00:00

  • HTA48 An Integrated Approach to HTA Assessments in the EU: Hype or Hope?

    Dec 1, 2022, 00:00

  • P58 Predicting the Risk of Stroke Using Machine Learning on a Large Administrative Health Database

    Dec 1, 2022, 00:00

  • HPR196 Patient Reported Outcome Measures Are of Profound Importance for the Success of Health Technology Assessments in Oncologic Indications in Germany

    Dec 1, 2022, 00:00

  • EE560 The Impact of Molecular Tumour Board on Costs and Patient Access to Personalized Medicine

    Dec 1, 2022, 00:00

  • HTA107 Direct Market Access for Medecines: Analysis of Eligible Products in France and Comparison With Current German System

    Dec 1, 2022, 00:00

  • HPR182 What Impact Did China's National Volume-Based Procurement Have on Drug Use Pattern and Clinical Benefit? Taking Amlodipine as an Example

    Dec 1, 2022, 00:00

  • EE431 The Cost-Effectiveness of Home-Based Cardiac Rehabilitation Interventions: A Systematic Review

    Dec 1, 2022, 00:00

  • EE650 Cost Effectiveness of Siponimod for Secondary Progressive Multiple Sclerosis in Turkey

    Dec 1, 2022, 00:00

  • PCR129 Demonstrating the Value of RWE Gained From Online Health Platforms: Understanding and Reducing Burden in Rheumatoid Arthritis

    Dec 1, 2022, 00:00

  • HTA1 Accounting for Placebo Effects in NICE Technology Appraisals of Biologic Therapies: A Comprehensive Review and Future Recommendations

    Dec 1, 2022, 00:00

  • EE363 Long Term Costs Assessment of Oral Therapies for Patients With Relapsing Multiple Sclerosis Based on the Evidence From a Large Real-World Study – Application to a Portuguese National Academic Hospital Center

    Dec 1, 2022, 00:00

  • EE17 Economic Evaluation of Patiromer for the Treatment of Hyperkalaemia in CKD Patients With and Without HF in Italy

    Dec 1, 2022, 00:00

  • Applications of Machine Learning and Artificial Intelligence in Real-World Studies

    Dec 1, 2022, 00:00

  • MT43 Evidence Generation of Digital Health Applications in Germany – An Overview of the Status Quo

    Dec 1, 2022, 00:00

  • EPH145 Treatment Patterns Among Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Ineligible for Transplantation – A Real-World Study Using French PMSI

    Dec 1, 2022, 00:00

  • PCR206 Evaluation of a Multimorbidity Patient-Centered Care Model Implemented in the Chilean Public Health System: Users´ Perspective

    Dec 1, 2022, 00:00

  • CO6 Influence of Serum Phosphate on the Predictive Utility of Serum Alkaline Phosphatase for Renal Outcomes in Chronic Kidney Disease Patients – A Prospective Cohort

    Dec 1, 2022, 00:00

  • EPH142 The Burden of Metastatic or Inoperable HER2+ Breast Cancer on the Italian Health System

    Dec 1, 2022, 00:00

  • EE358 Efficiency of Third-Generation Antiseizure Medications in Spain for Drug-Resistant Epilepsy: A Cost-per-Number Needed to Treat Analysis

    Dec 1, 2022, 00:00

  • EE530 Cost Per Response, Remission and Endoscopic Improvement of Advanced Therapies of Bio-Exposed Patients With Moderately-to-Severely Active Ulcerative Colitis (UC) in France

    Dec 1, 2022, 00:00

  • MSR65 Survival Estimates Using Hazard Ratios Derived From Network Meta-Analyses: Is More Guidance Needed?

    Dec 1, 2022, 00:00

  • PCR10 Qualitative Analysis of Patient Characters, Interviews on the Burden of Neuronopathic Gaucher Disease in Japan

    Dec 1, 2022, 00:00

  • EE466 Budget Impact Analysis of Cemiplimab for First-Line (1L) Advanced Non-Small Cell Lung Cancer (NSCLC) With Programmed Cell Death-Ligand 1 (PD-L1)≥ 50% in Italy

    Dec 1, 2022, 00:00

  • HPR187 Assessing the Impact of Anti-PD-1/PD-L1 Inhibitors on Cancer Care Health and Budget in Greece

    Dec 1, 2022, 00:00

  • EE494 A Cost-Benefit Evaluation for Trivalent to Quadrivalent Influenza Vaccination Switch for 40+ Years Old Dyslipidemia Patients With and Without Previous Cardiovascular Event in Colombia

    Dec 1, 2022, 00:00

  • HPR17 Changing Landscape of Orphan Drug Reimbursement - Evidence From EU-4 and England

    Dec 1, 2022, 00:00

  • EE347 Treatment Patterns and Healthcare Resource Utilization (HRU) Among Patients With Multiple Sclerosis (MS) in Germany Treated With Nabiximols Between 2010 and 2020

    Dec 1, 2022, 00:00

  • RWD44 The Cost of Haemophilia in Adults, a Socioeconomic Survey of People With Severe Haemophilia in Latin America: The ‘Chess Latam’ Study

    Dec 1, 2022, 00:00

  • EE603 Economic Evaluation of C5 Inhibitors in Patients With Paroxysmal Nocturnal Haemoglobinuria – A Systematic Literature Review

    Dec 1, 2022, 00:00

  • HPR102 Exploring Alternative Financing Models and Early Access Schemes for Orphan Drugs: A Belgian Case Study

    Dec 1, 2022, 00:00

  • RWD15 A Retrospective Database Study to Describe the Prevalence, Patient Characteristics and Healthcare Burden of Prurigo Nodularis (PN) in England

    Dec 1, 2022, 00:00

  • PCR268 The Impact of Radiotherapy Non-Compliance on the Recurrence and Mortality of Breast Cancer Patients: A Systematic Review

    Dec 1, 2022, 00:00

  • MSR3 A Novel Approach for Minimizing Immortal Time Bias in Observational Studies

    Dec 1, 2022, 00:00

  • EE279 Cost-Utility Analysis of Lower or Higher Oxygenation Targets for Acute Hypoxaemic Respiratory Failure – A Registry-Based Secondary Analysis of the Randomised Hot-ICU Trial

    Dec 1, 2022, 00:00

  • SA65 Future Prophylaxis Strategies in RSV: End of the Status Quo

    Dec 1, 2022, 00:00

  • HTA2 Conditional Recommendations by the Canadian Agency for Drugs and Technologies in Health (CADTH)

    Dec 1, 2022, 00:00

  • RWD163 Age-Related Cataract: Patient Characteristics and Real-World Treatment Patterns in the United States

    Dec 1, 2022, 00:00

  • CO63 Platinum Free-Interval in Patients With Ovarian Cancer Across an Argentinian Database: OCEANIA Real-World Study

    Dec 1, 2022, 00:00

  • PCR27 Pediatric Outcomes Data Collection Instrument (PODCI) Assessment of Ambulatory Boys Treated With Fordadistrogene Movaparvovec (PF-06939926) for Duchenne Muscular Dystrophy (DMD)

    Dec 1, 2022, 00:00

  • HTA188 Does Size Matter? Impact of Population Size on Evidence Quality and Negotiation Outcome for Orphan Drugs in Germany

    Dec 1, 2022, 00:00

  • EE301 Cost-Effectiveness Analysis of Avelumab Plus Best Supportive Care (BSC) As First-Line Maintenance Treatment in Locally Advanced or Metastatic Urothelial Carcinoma (La/mUC) in France

    Dec 1, 2022, 00:00

  • RWD109 The Burden of R/R DLBCL in Finland: PFS of The First-Line Immunochemotherapy and HCRU of The Patients Diagnosed in 2015–2017 in The Hospital District of Southwest Finland

    Dec 1, 2022, 00:00

  • PCR52 Adherence/Compliance to HIV–1 Treatment Regimens in South Africa — A Targeted Literature Review

    Dec 1, 2022, 00:00

  • P24 Improved Estimation of Overall Survival and Progression-Free Survival for State Transition Modelling in Oncology

    Dec 1, 2022, 00:00

  • CO31 Associations Between CDR-Global and Meaningful Outcomes in Patients With Alzheimer's Disease

    Dec 1, 2022, 00:00

  • EPH35 Post-COVID Conditions in Hospitalized COVID-19 Patients in Germany

    Dec 1, 2022, 00:00

  • PCR163 Humanistic and Economic Burden of Pyruvate Kinase Deficiency: A Systematic Review of Literature

    Dec 1, 2022, 00:00

  • SA59 Is There Life for Pre-Prints After COVID-19?

    Dec 1, 2022, 00:00

  • PCR111 Assessing Anxiety and Depression Among Gravidas

    Dec 1, 2022, 00:00

  • PCR124 First-Line Treatment Patterns Among Patients With Locally Advanced or Metastatic Urothelial Cancer (la/mUC): A Systematic Literature Review

    Dec 1, 2022, 00:00

  • HTA18 Impact of The Use of Cost-Effectiveness Analysis (CEA) on Patient Access to Medicines: A Comparison of CEA vs Non-CEA Markets

    Dec 1, 2022, 00:00

  • HTA46 Outcomes of Benefit Assessments of Orphan Drugs Without Orphan Designation in Germany

    Dec 1, 2022, 00:00

  • HSD19 Which Elements Determine Prescribing Decisions for Off-Patent Biological Medicines in Belgium? A Qualitative Study

    Dec 1, 2022, 00:00

  • RWD76 Real-World Patient Persistence and Complian A Comparison of Prostaglandin Analogs Used for the Treatment of Open-Angle Glaucoma or Ocular Hypertension

    Dec 1, 2022, 00:00

  • PCR8 Exploring Preferences of Different Modes of Administration of Hypomethylating (HMA) Treatments Among Patients With Acute Myeloid Leukemia (AML)

    Dec 1, 2022, 00:00

  • HPR212 Solving the Mystery: Are There Variables That Could Positively Influence PR Approval of Orphan Drugs (ODs) in Spain?

    Dec 1, 2022, 00:00

  • CO147 Comparative Efficacy and Safety of Pharmacological Interventions for Managing Sickle Cell Disease Complications in Children and Adolescents: A Systematic Review With Network Meta-Analyses

    Dec 1, 2022, 00:00

  • HTA134 Current and Future Trends in PR Decisions of Oncology and Onco-Hematology Drugs in Spain: A Retrospective and Forum Discussion Study

    Dec 1, 2022, 00:00

  • EE545 Mapping Between Health and Broader Quality of Life Instruments: A Scoping Review

    Dec 1, 2022, 00:00

  • EE586 Cost-Utility of Cladribine Tablets and Dimethyl Fumarate in the Treatment of Relapsing Remitting Multiple Sclerosis From the Societal Perspective in Spain

    Dec 1, 2022, 00:00

  • MSR78 Population Attributable Fraction Based on Sufficient Causal Framework for Mediation Settings - Evaluation of Resource Distribution on Prevention and Treatment for Stroke

    Dec 1, 2022, 00:00

  • CO67 Tafasitamab Plus Lenalidomide (TAFA+LEN) Versus Pola-BR, R2, and CAR-T in Non-Transplant Eligible (NTE) Relapsed/Refractory (R/R) DLBCL: A Post Hoc Analysis of the RE-MIND2 Study Comparing Multiple Cohort-Balancing Approaches

    Dec 1, 2022, 00:00

  • MSR70 A Head-to-Head Comparison of the EQ-5D-5L and 15D Descriptive Systems and Index Scores in a General Population Sample

    Dec 1, 2022, 00:00

  • EE351 Recognising the Broader Value of Meningococcal Vaccination: A Matter of Evidence, Ability or Willingness?

    Dec 1, 2022, 00:00

  • MSR27 Lessons Learned From Successful Real-World Evidence (RWE) Studies Supporting Drug Effectiveness in Regulatory Approvals

    Dec 1, 2022, 00:00

  • HPR213 Comparative Analysis of Access to Advanced Therapy Medicine Products (ATPM) in Latin America

    Dec 1, 2022, 00:00

  • CO78 Matching-Adjusted Indirect Comparison of Futibatinib Versus Chemotherapy and Pemigatinib in Cholangiocarcinoma Patients With FGFR2 Fusions/Rearrangements

    Dec 1, 2022, 00:00

  • HTA178 High-Energy Devices and Standard Monopolar/Bipolar Devices: An HTA in the Italian Surgical Setting

    Dec 1, 2022, 00:00

  • EPH51 The Health and Economic Burden of Bushfires in Australia Between 2021 and 2030: A Modelling Study

    Dec 1, 2022, 00:00

  • HTA15 An Evaluation of Health Technology Assessment (HTA) Requirements for Emerging Therapies in Alzheimer’s Disease (AD)

    Dec 1, 2022, 00:00

  • EE120 Real-World Utilisation of Damoctocog Alfa Pegol in Adults With Haemophilia A: Second Interim Analysis of the HEM-POWR Observational Study

    Dec 1, 2022, 00:00

  • CO118 TRK Inhibitor Treatment Patterns in Patients with NTRK Fusion-Positive Solid Tumors: A Multi-Site Cohort Study at U.S. Academic Cancer Centers

    Dec 1, 2022, 00:00

  • EE635 Direct Comparison of Prophylaxis Cost in Patients With Severe Hemophilia A With and Without Inhibitors With Hemostatic Agents Versus the Use of Emicizumab in Guatemala

    Dec 1, 2022, 00:00

  • RWD18 Underappreciation of Disease Burden in Female Patients With Axial Spondyloarthritis (AxSpA) in Real-World Care

    Dec 1, 2022, 00:00

  • HSD93 Investigating the Impact of COVID-19 on Haemodialysis

    Dec 1, 2022, 00:00

  • EE342 Pancreatic Exocrine Insufficiency in Patients Who Have Undergone Surgery Due to Pancreatic Cancer: A Chinese Cost-Utility Analysis

    Dec 1, 2022, 00:00

  • CO58 Matching-Adjusted Indirect Comparison (MAIC) of Tepotinib With Capmatinib in Previously Treated Advanced Non-Small Cell Lung Cancer (aNSCLC) With MET Exon 14 (METex14) Skipping

    Dec 1, 2022, 00:00

  • HTA44 Utilisation of Societal Costs in the NICE HST Approvals Compared to European Agencies

    Dec 1, 2022, 00:00

  • EE105 Cost-Effectiveness of Recombinant Factor IX Fc Prophylaxis and Recombinant Factor IX On-Demand Treatment in Patients With Haemophilia B Without Inhibitors

    Dec 1, 2022, 00:00

  • HSD12 Reasons for Choice and Areas for Improvements of Advanced Therapies (Biologics and Janus Kinase Inhibitors) for Patients With Ulcerative Colitis in the United Kingdom

    Dec 1, 2022, 00:00

  • HTA125 The Relationship Between Value and Price in the Free-Pricing Period and Post-Assessment Price in Germany: A Case Study in Rheumatoid Arthritis

    Dec 1, 2022, 00:00

  • EE8 Cost of Arthropathic Diseases Therapy: A 5-Year Budget Analysis at National Level

    Dec 1, 2022, 00:00

  • PCR107 General and Scalable Versus Disease-Specific and Targeted: To What Extent Should We Measure Outcomes From These Two Areas?

    Dec 1, 2022, 00:00

  • HTA111 Health Technology Assessment on Thermalytix; A Novel Breast Cancer Screening Technology

    Dec 1, 2022, 00:00

  • EPH154 The Connection Between the Lunar Cycles and the Number of Births in Hungary

    Dec 1, 2022, 00:00

  • PCR38 To What Extent Are Long-Term Breast Cancer Survivors Subjected to Financial Burden in Germany? Results From a Patient Survey-Based Study

    Dec 1, 2022, 00:00

  • P34 Subclinical Hypothyroidism Influences the Quality of Life During Pregnancy: Results From THYPREQOL2020

    Dec 1, 2022, 00:00

  • CO171 Use of Patient-Reported Outcomes (PROs) and Its Implementation in Clinical Care in India: A Clinician's Perspective

    Dec 1, 2022, 00:00

  • MSR90 Moving Beyond QALYs: A Composite Indicator to Measure the Benefit of Hearing Implants

    Dec 1, 2022, 00:00

  • EPH93 Drivers of Treatment Decisions in Multiple Myeloma Front-Line Transplant-Eligible Patients in a Real-World Setting: A Qualitative Assessment of Physicians’ Perspectives in Europe

    Dec 1, 2022, 00:00

  • HPR124 Utilising Health Economics to Enable Optimal Transition From a Platform Technology to a Development Programme and Product

    Dec 1, 2022, 00:00

  • PCR120 Psychometric Properties of the Hungarian PROMIS Global Health Questionnaire

    Dec 1, 2022, 00:00

  • HSD55 Expanding Vaccine Competencies to Community Pharmacists: Modelling Organizational and Economic Impacts of New Human Papilloma Virus (HPV) Vaccines Pathways in France

    Dec 1, 2022, 00:00

  • MSR137 The Impact of the Proportion of Cured and Length of Follow-up on Mixture Cure Models (MCMS): A Simulation Study

    Dec 1, 2022, 00:00

  • RWD94 A Retrospective Study of Treatment Disparities in Demographics for Major Depressive Disorder (MDD) Using Claims Data in the US

    Dec 1, 2022, 00:00

  • EE538 Cost Analysis, Cost-Effectiveness, and Cost-Utility of Hypertension and Hyperlipidemia Collaborative Management Between Pharmacies and Primary Care in Portugal Alongside a Trial Compared With Usual Care (USFarmácia®)

    Dec 1, 2022, 00:00

  • HPR65 Prevalence as a Driver of Treatment Cost for Drugs in the Rare Disease Field in Italy

    Dec 1, 2022, 00:00

  • HPR147 Evaluating the Misdiagnosis of Add in Patients With Prior History of Depression: A Claims Data Study in Germany

    Dec 1, 2022, 00:00

  • PCR71 Off Episode Quality of Life Impact Scale (OFFELIA): Overview of the Development of a Quality of Life and Functional Impact Measure of Off Episodes in Parkinson's Disease

    Dec 1, 2022, 00:00

  • HTA136 Impact on Scottish Medicines Consortium Reimbursement Decisions When Assessed Under the Orphan Drug Process

    Dec 1, 2022, 00:00

  • EE72 Magnetic Resonance Imaging-Based Prostate Cancer Screening: Differences in the Cost-Effectiveness Using Evidence From Diagnostic Cohorts Versus Screening-by-Invitation Trial

    Dec 1, 2022, 00:00

  • PCR57 An Empirical Comparison of Data From Forced vs Non-Forced Choices in a Dual Response Discrete Choice Experiment, With Breast Cancer Patients in Six European Countries

    Dec 1, 2022, 00:00

  • EE306 Cost-Consequence Analysis of EPTFE Vascular Grafts With Heparin End Point Covalent Bond Compared to Standard EPTFE Vascular Grafts in Below-Knee Surgical Bypass for Critical Limb Ischemia Pad Patients in Germany

    Dec 1, 2022, 00:00

  • EE294 Cost-Effectiveness of Left Ventricular Assist Devices as Destination Therapy: An Economic Modelling Study

    Dec 1, 2022, 00:00

  • EE275 Personalised Versus Standard Dosimetry for Selective Internal Radiation Therapy in Patients With Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

    Dec 1, 2022, 00:00

  • HPR79 A Qualitative Exploration of Drivers of Cannabis Purchase Decisions in Canada

    Dec 1, 2022, 00:00

  • EE658 Budget Impact Analysis for Multi-Indication Targeted Therapy: A Case Study of Cabozantinib Cost-Saving in Algeria as Treatment Option in First-Line Second-Line Renal-Cell Carcinoma and Second-Line Hepatocellular Carcinoma

    Dec 1, 2022, 00:00

  • P16 Antineoplastic Agents in Ovarian Cancer Treatment Using Argentinian Real-World Data: OCEANIA Study

    Dec 1, 2022, 00:00

  • EE377 Healthcare Utilization and Costs Among Acutely Hospitalized Older Adults

    Dec 1, 2022, 00:00

  • EPH190 Premature Mortality From Ischaemic Heart Disease Among Men in Hungary by District

    Dec 1, 2022, 00:00

  • MT18 Patient Acceptance to Valuing Digital Technologies: A Discrete Choice Experiment

    Dec 1, 2022, 00:00

  • HTA79 Time-Driven Activity-Based Costing to Compare the Cost of Administering Bronchodilators by Metered Dose Inhalers and by Nebulization in the Emergency Department

    Dec 1, 2022, 00:00

  • RWD140 Benefits and Challenges of Deterministic, Probabilistic, and Patient-Mediated Approaches to Linking Patients’ Clinical Trial Data (CTD) and Their Real-World Data (RWD)

    Dec 1, 2022, 00:00

  • HPR140 Assessing the Influence of the Orphan Drug Status on Medicine Prices in the EU4 + UK

    Dec 1, 2022, 00:00

  • PCR148 Patient Involvement in the Development of Outcomes Measures Specific to Neuronopathic Gaucher Disease Type 2 and Type 3 to Assess HRQoL Over the Disease Journey

    Dec 1, 2022, 00:00

  • EE240 Does Single Stage Surgery of Long Bone Infection Using Gentamicin-Eluting Bone-Graft Substitutes Result in Decreased Cost and Improved Quality of Life Compared to Traditional Approaches?

    Dec 1, 2022, 00:00

  • EPH56 Trends in Human Papillomavirus (HPV) Vaccine Coverage Rates (VCR) in Fran A Claims Data Study

    Dec 1, 2022, 00:00

  • EPH87 Safety of Interchanging From Reference Biologic to its Biosimilar: A Systematic Review and Meta-Analysis

    Dec 1, 2022, 00:00

  • EE126 Cost-Effectiveness of Multi-Cancer Early Detection (MCED) Testing Using Mixture Cure Modeling (MCM)

    Dec 1, 2022, 00:00

  • MSR35 Systematically Validating Health Economic Models Using the Probabilistic Analysis Check Dashboard (PACBOARD)

    Dec 1, 2022, 00:00

  • P8 Role Preferences in Medical Decision Making: Implications for Health Preference Research

    Dec 1, 2022, 00:00

  • PCR285 Burden of Itch Among Patients With Chronic Kidney Disease/End-Stage Kidney Disease Receiving Hemodialysis: Results From a Prospective Patient-Reported Survey in the USA

    Dec 1, 2022, 00:00

  • PCR238 Oral Nutritional Supplementation in Pediatric Patients Diagnosed With Leukaemia Undergoing Chemotherapy: A Review of the Literature

    Dec 1, 2022, 00:00

  • HTA28 Use of Synthetic Data Derived From Electronic Health Records to Augment Clinical Trial Data Evaluating First Line Therapy in Malignant Pleural Mesothelioma

    Dec 1, 2022, 00:00
  • «
  • 21
  • 22
  • 23
  • 24
  • 25
  • 26
  • 27
  • 28
  • 29
  • 30 (current)
  • »